GlassScriptPhysician profile
Teresa M Menadier
NPI 1679835383
$794.71
in general payments reported to CMS, 2019-2025
9 companies · $68.92 in 2025
The $68.92 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2023: $120 · 2024: $383 · 2025: $68.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $127.70 | 2019 | |
| Janssen Biotech, INC. | $125.00 | 2024 | Tremfya, Stelara |
| Novo Nordisk INC | $119.63 | 2023 | Wegovy |
| Genzyme Corporation | $101.51 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.97 | 2019 | |
| Medtronic, INC. | $87.49 | 2024 | Endoflip |
| Abbvie INC. | $56.19 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $49.49 | 2024 | Everlift |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2025 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Menadier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.